PRAX
Praxis Precision Medicines, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 28 ▲ Six major institutional investors significantly increased or establi…
- Feb 28 ▲ Three major passive institutional investors, Morgan Stanley, Wells F…
- Mar 30 ▲ Praxis Precision Medicines announced FDA acceptance of its NDA for r…
- Apr 6 ▲ Praxis Precision Medicines announced positive topline results from t…
- Apr 14 ▲ Praxis Precision Medicines announced that the FDA has accepted its N…
- May 7 ▲ Praxis Precision Medicines reported Q1 2026 EPS of -$3.20 (GAAP), a…
- Jun 24 ▼ 1 insider sell $3.6M at $311.32
- Jun 29 ▼ Praxis Precision Medicines announced a 3-month FDA extension of the…
- Sep 30 ▲ 4 funds open new positions (13F)
- Oct 16 JP Morgan initiates
- Nov 4 Activist stake: Praxis Precision Medicines, Inc. Announces Inducement Gran…
- Nov 9 ▲ Earnings: PRAX Q3 2026 Earnings: EPS $-3.23 (+16.1% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider sold $3.6M.
- InstitutionsBULLISH
Q3 2026: 42 added (4 new), 14 trimmed or exited. Largest new: Quadrature Capital $14.6M, Fiera Capital $11.7M.
- AnalystsBULLISH
24 of 27 rate it Buy or better.
- EstimatesFLAT
Current-quarter EPS estimate −$3.635 → −$3.635 over 90 days.
- Short sellersSTEADY
Short interest +7.3% to 4.21M shares. 8.7 days to cover, ≈15.1% of shares.
- TrendUPTREND
7% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FRANKLIN TEMPLETON INC | ADD | $165.8M |
| WESTFIELD CAPITAL MANAGEMENT CO LP | ADD | $111.3M |
| MARSHALL WACE, LLP | ADD | $64.5M |
| Qube Research & Technologies Ltd | TRIM | $29.6M |
| Aberdeen Group plc | TRIM | $28.0M |
| JANE STREET GROUP, LLC | DOUBLED | $23.7M |
| Nuveen, LLC | TRIM | $20.4M |
| JUPITER ASSET MANAGEMENT LTD | DOUBLED | $16.2M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
27 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 16, 2026 | 🔒 Fresh data, subscribers only MAINTAIN | |
| Nov 16, 2026 | 🔒 Fresh data, subscribers only MAINTAIN | |
| Nov 10, 2026 | RBC Capital MAINTAIN | Outperform |
| Nov 10, 2026 | Wedbush MAINTAIN | Underperform |
| Nov 10, 2026 | Wells Fargo MAINTAIN | Equal-Weight |
| Nov 9, 2026 | BTIG REITERATE | Buy |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Souza Marcio Chief Executive Officer Jul 8, 2026 | GIFT | 2,600 sh |
Souza Marcio Chief Executive Officer Jul 8, 2026 | GIFT | 20,521 sh |
DeSimone Jill Director Jun 24, 2026 | EXERCISE | $379.0K |
DeSimone Jill Director Jun 24, 2026 | SELL | $3.0K |
DeSimone Jill Director Jun 24, 2026 | EXERCISE | $446.9K |
DeSimone Jill Director Jun 24, 2026 | SELL | $36.4K |
DeSimone Jill Director Jun 24, 2026 | SELL | $97.7K |
DeSimone Jill Director Jun 24, 2026 | SELL | $209.5K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$3.63 | -$5.60–-$2.74 | -0.1% | $0.00 |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
11 filings · 5 press releases · 3 bullish · 2 bearish · 1 mixed · 5 neutral- BEARISH SC 13G/ANov 16, 2026
Orbis Investment Management Ltd filed an amended Schedule 13G disclosing a 4.9% passive stake in Praxis Precision Medicines as of September 30, 2026, down from 9.2% in the prior filing. The reduction from 2,565,828 shares to 1,356,279 shares represents a significant decrease, signaling the fund is…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 8-KNov 12, 2026
Praxis Precision Medicines hosted an Investor Day on November 12, 2026, presenting commercial…
Key catalysts over next 12 months: relutrigine PDUFA Dec 27, 2026; ulixacaltamide PDUFA Jan 29, 2027; EMERALD broad DEE topline 4Q26; EMBRAVE3 elsunersen topline 2027; PRAX-215 Phase 1 readout 2027…
- NEUTRAL PRESS-RELEASENov 9, 2026
Praxis Precision Medicines reported Q3 2026 net loss of $94.2M ($3.23 per share), wider than the…
The stock's near-term catalyst path is binary: relutrigine PDUFA on Dec 27 and ulixacaltamide PDUFA on Jan 29. The EMERALD readout in Q4 adds another binary event. Monitor FDA advisory committee…
- NEUTRAL SC 13G/ANov 5, 2026
FMR LLC (Fidelity) filed an amended Schedule 13G disclosing beneficial ownership of 2,565,828…
FMR's passive 9.2% stake is a routine update with no change in investment stance. Monitor for any future conversion to Schedule 13D, which would signal activist intent, but no such indication exists…
All PRAX filing & press-release reports (16)
- SC 13G/A reportNov 16, 2026
- 8-K reportNov 12, 2026
- PRESS-RELEASE reportNov 9, 2026
- SC 13G/A reportNov 5, 2026
- PRESS-RELEASE reportNov 4, 2026
- INST-CLUSTER reportOct 29, 2026
- 8-K reportJun 29, 2026
- INST-CLUSTER reportJun 11, 2026
- PRESS-RELEASE reportJun 2, 2026
- PRESS-RELEASE reportMay 7, 2026
- PRESS-RELEASE reportMay 4, 2026
- PRESS-RELEASE reportApr 14, 2026
- PRESS-RELEASE reportApr 6, 2026
- PRESS-RELEASE reportMar 30, 2026
- INST-CLUSTER reportFeb 28, 2026
- INST-CLUSTER reportFeb 28, 2026